Recombinant alpha-2a interferon treatment in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC): Clinical and immunological evaluation

I. Mezzaroma, A. Avella, R. Paganelli, B. Ensoli, G. D'Offizi, M. C. Sirianni, G. Luzi, C. Valdarchi, F. Aiuti

Research output: Contribution to journalArticle

Abstract

We evaluated the clinical efficacy and tolerability of recombinant alpha 2a interferon (IFN), in a group of 16 patientss with AIDS and ARC, including 3 children. All patients were followed up monthly for clinical and immunological studies. The frequency of opportunistic infections (OI) in AIDS, and the following symptoms in all patients were studied: fever, night sweats, fatigue, diarrhoea, weight loss. Immunological parameters (CD3+, CD4+, CD8+ lymphocytes, skin tests to recall antigens, NK activity, lymphoproliferative response to PHA) were also evaluated. Adult patients were treated with 3-6 million IU of r-alpha 2a IFN daily im for 3 months and the 3 times weekly up to 12 months. Pediatric cases were treated with lower doses of 0.5-1.5 million IU using the same time schedule. We observed clinical improvement and reduction of severe infections in 10/15 evaluable patients (4/4 ARC and 6/11 AIDS). Immunological parameters were transiently improved in one third of cases. We observed only mild side effects in r-alpha IFN treatment. We suggest therapy with r-alpha 2a IFN at low dosage should be tried in patients with AIDS for its beneficial effects on OI development.

Original languageEnglish
Pages (from-to)201-207
Number of pages7
JournalAllergologia et Immunopathologia
Volume19
Issue number5
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Recombinant alpha-2a interferon treatment in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC): Clinical and immunological evaluation'. Together they form a unique fingerprint.

  • Cite this